Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lorlatinib

FDA-approved product (tablet, oral), marketed as Lorbrena.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lorlatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lymphoma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lorlatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lorlatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

    NCT06586801 · start 2024-09-20

    Registered record
    Registry ID
    NCT06586801
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Patient-reported outcome
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-09-20
    Completion
    2026-09-30
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionPatient-reported outcome
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

    NCT06282874 · start 2024-08-01

    Registered record
    Registry ID
    NCT06282874
    Conditions
    Carcinoma, Non-Small-Cell Lung; Brain Metastases; Leptomeningeal Metastasis
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-08-01
    Completion
    2027-03-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Brain Metastases; Leptomeningeal Metastasis
    InterventionLorlatinib
    PhasePhase 4
    Registry statusActive not recruiting

  • Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

    NCT06361589 · start 2024-05-01

    Registered record
    Registry ID
    NCT06361589
    Conditions
    ALK-positive Non-small Cell Lung Cancer; Real World Study
    Interventions
    Lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-05-01
    Completion
    2028-11-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small Cell Lung Cancer; Real World Study
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusRecruiting

  • Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

    NCT05948462 · start 2023-11

    Registered record
    Registry ID
    NCT05948462
    Conditions
    Lung Cancer; Non-small Cell Lung Cancer
    Interventions
    Lorlatinib; Cisplatin or Carboplatin; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-11
    Completion
    2025-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Non-small Cell Lung Cancer
    InterventionLorlatinib; Cisplatin or Carboplatin; Pemetrexed
    PhasePhase 2
    Registry statusWithdrawn

  • Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

    NCT06092086 · start 2023-08-18

    Registered record
    Registry ID
    NCT06092086
    Conditions
    ALK Positive Non-small Cell Lung Cancer
    Interventions
    Loratinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-08-18
    Completion
    2030-08-01
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive Non-small Cell Lung Cancer
    InterventionLoratinib
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

    NCT05297890 · start 2022-05-27

    Registered record
    Registry ID
    NCT05297890
    Conditions
    Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-05-27
    Completion
    2027-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
    InterventionLorlatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

    NCT05224609 · start 2022-04-28

    Registered record
    Registry ID
    NCT05224609
    Conditions
    Moderate Hepatic Impairment; Severe Hepatic Impairment; Healthy Volunteers
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-28
    Completion
    2024-08-13
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Hepatic Impairment; Severe Hepatic Impairment; Healthy Volunteers
    InterventionLorlatinib
    PhasePhase 1
    Registry statusCompleted

  • Personalized DC Vaccines in Non Small Cell Lung Cancer

    NCT05195619 · start 2022-03-22

    Registered record
    Registry ID
    NCT05195619
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-03-22
    Completion
    2027-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAutologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    PhasePhase 1
    Registry statusActive not recruiting

  • Lorlatinib Continuation Study

    NCT05144997 · start 2021-12-28

    Registered record
    Registry ID
    NCT05144997
    Conditions
    Non-Small-Cell Lung Cancer; NSCLC
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2021-12-28
    Completion
    2026-12-28
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Cancer; NSCLC
    InterventionLorlatinib
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

    NCT05167500 · start 2021-12-09

    Registered record
    Registry ID
    NCT05167500
    Conditions
    Metastatic Non Small Cell Lung Cancer
    Interventions
    Lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-09
    Completion
    2022-12-30
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non Small Cell Lung Cancer
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusCompleted

  • Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

    NCT04979988 · start 2021-08-02

    Registered record
    Registry ID
    NCT04979988
    Conditions
    ALK-positive Non-small-cell Lung Cancer
    Interventions
    Lortlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-02
    Completion
    2021-12-09
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small-cell Lung Cancer
    InterventionLortlatinib
    PhaseNot recorded
    Registry statusCompleted

  • Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

    NCT04753658 · start 2021-03-19

    Registered record
    Registry ID
    NCT04753658
    Conditions
    Neuroblastoma
    Interventions
    lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-03-19
    Completion
    2022-09-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    Interventionlorlatinib
    PhaseNot recorded
    Registry statusTerminated

  • PF-07284892 in Participants With Advanced Solid Tumors

    NCT04800822 · start 2021-03-17

    Registered record
    Registry ID
    NCT04800822
    Conditions
    Solid Tumor
    Interventions
    PF-07284892; lorlatinib; binimetinib; cetuximab; encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-03-17
    Completion
    2024-06-19
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionPF-07284892; lorlatinib; binimetinib; cetuximab +1 more
    PhasePhase 1
    Registry statusTerminated

  • Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

    NCT04647110 · start 2020-12-14

    Registered record
    Registry ID
    NCT04647110
    Conditions
    ALK-positive NSCLC
    Interventions
    crizotinib; alectinib; brigatinib; ceritinib; lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-14
    Completion
    2021-03-15
    Enrolment
    549

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive NSCLC
    Interventioncrizotinib; alectinib; brigatinib; ceritinib +1 more
    PhaseNot recorded
    Registry statusCompleted